Adagio Medical Holdings, Inc. filed a Form 8-K on November 5, 2026, disclosing that it filed a Certificate of Amendment with the State of Delaware on November 4, 2026 to effect a one-for-thirty reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on November 6, 2026.

Key Highlights

  • Split ratio: Every 30 shares of outstanding common stock will automatically be combined into 1 share, with no change in par value per share.
  • Effective time: The Amendment becomes effective at 5:00 p.m. Eastern Time on November 6, 2026.
  • Trading adjustment: Common stock will begin trading on a split-adjusted basis when the market opens on November 9, 2026.
  • New CUSIP: The new CUSIP number for the common stock following the reverse stock split is 00534B308.
  • Stockholder approval: A series of alternate amendments was approved at a Special Meeting of Stockholders held on October 23, 2026; the board of directors approved the specific 1-for-30 ratio on October 23, 2026.
  • Fractional shares: No fractional shares will be issued; stockholders otherwise entitled to a fractional share will receive a cash payment in lieu thereof.

Details of Adagio Medical Holdings' 1-for-30 Reverse Stock Split

According to the filing, Adagio Medical Holdings, Inc. (NASDAQ:ADGM) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on November 4, 2026. The Amendment effects a one-for-thirty (1-for-30) reverse stock split of the company's outstanding common stock, with an effective time of 5:00 p.m. Eastern Time on November 6, 2026. The company disclosed that its common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on November 9, 2026.

The filing states that the reverse stock split will affect all shares of the company's common stock outstanding immediately prior to the effective time. Proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon exercise or vesting of all outstanding stock options, resulting in a proportionate decrease in shares reserved and a proportionate increase in exercise prices. The company also disclosed that all outstanding restricted stock unit awards and warrants will be proportionately adjusted, and shares reserved under equity compensation plans will be reduced proportionately.

The filing further states that the reverse stock split will affect all stockholders proportionately and "will not affect any stockholder's percentage ownership of the Company's common stock (except to the extent that the Reverse Stock Split results in any stockholder owning only a fractional share)." The company's new CUSIP number following the reverse stock split is 00534B308. The filing was signed by Deborah Kaster, Chief Financial Officer and Chief Business Officer.

What Was Disclosed

Adagio Medical Holdings filed an 8-K reporting a 1-for-30 reverse stock split effective November 6, 2026, with split-adjusted trading beginning November 9, 2026 on The Nasdaq Capital Market, and a new CUSIP number of 00534B308.